One institutions' experience with a true standard 15 mCi dose of I-131 for the treatment of Graves' disease.
Journal
Nuclear medicine communications
ISSN: 1473-5628
Titre abrégé: Nucl Med Commun
Pays: England
ID NLM: 8201017
Informations de publication
Date de publication:
01 Jan 2023
01 Jan 2023
Historique:
entrez:
14
12
2022
pubmed:
15
12
2022
medline:
16
12
2022
Statut:
ppublish
Résumé
Currently, there is a lack of consensus on the fixed dosage of RAI to be administered for this purpose between the main guideline frameworks set forth by the American Thyroid Association (ATA), Society of Nuclear Medicine and Molecular Imaging (SNMMI), European Association of Nuclear Medicine (EANM) and the European Thyroid Association (ETA). In this retrospective study, we will investigate the effectiveness of using a standard dose of 15 mCi ±10% of RAI in the treatment of Graves'. A retrospective chart review was conducted for the period between 1 May 2014 and 2 September 2020, to identify patients diagnosed with hyperthyroidism due to Graves' disease. The patients were grouped based on outcome and assessed for the efficacy of the dosage of 15 mCi ±10% of RAI in a successful treatment. Sixty-seven patients were identified that met the inclusion criteria between 1 May 2014 and 2 September 2020. Of the 67 RAI ablations; 60 patients became hypothyroid [60/67, (89.55%)], 2 euthyroid [2/67, (2.99%)] and 5 remained hyperthyroid [5/67, (7.46%)]. For the treatment of Graves' disease, the use of a standard low dose of 15 mCi ±10% has a high success rate without additional measurements or calculations beyond a standard planar image and 24-h uptake %. The adoption of a standard low dose of 15 mCi of I-131 across institutional guidelines would streamline dosage questions and eliminate the need to determine the weight of the thyroid for calculations in all RAI treatments for hyperthyroidism caused by Graves' disease.
Identifiants
pubmed: 36514928
doi: 10.1097/MNM.0000000000001633
pii: 00006231-202301000-00007
doi:
Substances chimiques
Iodine-131
0
Iodine Radioisotopes
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
49-55Informations de copyright
Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.
Références
Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 2016; 26:1343–1421.
De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet 2016; 388:906–918.
Hussain YS, Hookham JC, Allahabadia A, Balasubramanian SP. Epidemiology, management and outcomes of Graves’ disease-real life data. Endocrine 2017; 56:568–578.
Pokhrel B, Bhusal K. Graves disease. StatPearls 2022. https://www.ncbi.nlm.nih.gov/books/NBK448195/ . [Accessed January 2022].
Burch HB, Burman KD, Cooper DS. A2011 survey of clinical practice patterns in the management of Graves’ disease. J Clin Endocrinol Metab 2012; 97:4549–4558.
Silberstein EB, Alavi A, Balon HR, Clarke SE, Divgi C, Gelfand MJ, et al. The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0*. J Nucl Med 2012; 53:1633–1651.
Stokkel MP, Junak DH, Lassmann M, Dietlein M, Luster M. 2012 EANM procedure guidelines for therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging 2012; 37:2218–2228.
Kahaly GJ, Bartalena L, Hegedus L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association guideline for the management of Graves’ hyperthyroidism. Eur Thyroid J 2018; 7:167–186.
Firth D. ‘Bias reduction of maximum likelihood estimates’. Biometrika 1993; 80:27–38.
Benjamini Y, Hochberg Y. ‘Controlling the false discovery rate: a practical and powerful approach to multiple testing’. J R Stati Soc Ser B 1995; 57:289–300.
Kung AW, Yau CC, Cheng AC. The action of methimazole and L-thyroxine in radioiodine therapy: a prospective study on the incidence of hypothyroidism. Thyroid 1995; 5:7–12.
Bonnema SJ, Bennedbaek FN, Veje A, Marving J, Hegedus L. 2004 Propylthiouracil before 131I therapy of hyperthyroid disease: effect on cure rate evaluated by a randomized clinical trial. J Clin Endocrinol Metab 2004; 89:4439–4444.
Santos RB, Romaldini JH, Ward LS. A randomized controlled trial to evaluate the effectiveness of 2 regimens of fixed iodine (131I) doses for Graves disease treatment. Clin Nucl Med 2012; 37:241–244.
Braga M, Walpert N, Burch HB, Solomon BL, Cooper DS. The effect of methimazole on cure rates after radioiodine treatment for Graves’ hyperthyroidism: a randomized clinical trial. Thyroid 2002; 12:135–139.
Santos RB, Romaldini JH, Ward LS. Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patient with Grave’s disease. Thyroid 2004; 14:525–530.
Ceccarelli C, Bencivelli W, Vitti P, Grasso L, Pinchera A. Outcome of radioiodine -131 therapy in hyperfunctioning thyroid nodules: a 20 years’ retrospective study. Clin Endocrinol 2005; 62:331–335.
Ratcliffe GE, Coke S, Fogelman I, Maisey MN. 1986 Radioiodine treatment of solitary functioning nodules. Br J Radiol 1986; 59:385–387.
Sanyal D, Mukhhlopadhyay P, Pandit K, Chatterjee J, Raychaudhuri M, Mukherjee S, et al. Early treatment with low fixed dose (5 mCi) radioiodine therapy in effective in Indian subjects with Graves’ disease. J Indian Med Assoc 2008; 106:360–361, 372.
Canadas V, Vilar L, Moura E, Brito A, Castellar E. Evaluation of radioiodine therapy with fixed doses of 10 and 15 mCi in patients with Graves’ disease. Arq Bras Endocrinol Metab 2007; 51:1069–1076.
Collier A, Gosh S, Hair M, Malik I, McGarvie J. Comparison of two fixed activities of radioiodine therapy (370 vs 555 MBq) in patients with Graves’ disease. Hormones (Athens) 2009; 8:273–278.
Bonnema SJ, Hegedus L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcomes. Endocr Rev 2012; 33:920–980.
Grosso M, Traino A, Boni G, Banti E, Della Porta M, Manca G. Comparison of different thyroid committed doses in radioiodine therapy for Graves’ hyperthyroidism. Cancer Biother Radiopharm 2005; 20:218–223.
Halstenberg J, Kranert W, Korkusuz H, Mayer A, Ackermann H, Grunwald F, et al. Influence of glucocorticoid therapy on intratherapeutic biodistribution of I-131 radioiodine therapy in Graves’ disease. Nuklearmedizin 2018; 57:43–49.
Murakami Y, Takamatsu J, Sakane S, Kuma K, Ohsawa N. Changes in thyroid volume in response to radioactive iodine for graves’ hyperthyroidism correlated with activity of thyroid-stimulating antibody and treatment outcome. J Clin Endocrinol Metab 1996; 81:3257–3260.
Chiovato L, Fiore E, Vitti P, Rocchi R, Rago T. Outcome of thyroid function in graves’ patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blokcing antibodies and of radioiodine-induced thyroid damage. J Clin Endocrinol Metab 1997; 83:40–46.